Skip to content
AnalystLens

DEXCOM INC 8-K Report, Executive Changes (Dec 22, 2025)

Reports
Leadership Changes·Exhibits & Filings
Filing Date
Filed December 22, 2025
Period End
December 19, 2025
Security
DXCM
In the record · 2016–202610-K1110-Q328-K134

DXCM filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 134 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · May ’17May ’17
  2. Material agreement8-K · May ’20May ’20
  3. Leadership change8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Mar ’25Mar ’25

01—Abstract

Summary

Summary of the 8-K filed December 22, 2025. Cited figures are marked; the original filing is the authoritative source.

DexCom, Inc. (DXCM) has filed an 8-K report detailing the official appointment of Jacob S.

Leach as President and Chief Executive Officer, effective January 1, 2026. This transition follows Mr. Leach's service as interim principal executive officer during Kevin R. Sayer's medical leave.

The filing outlines the key terms of Mr. Leach's new role, including an annual base salary of $1,150,000a and a target bonus opportunity of 150% of his base salary. Furthermore, Mr. Leach will receive significant equity awards, comprising restricted stock units valued at $7,500,000 and performance stock units with a target value of $7,500,000, both vesting over several years and contingent on continued service and performance conditions. This leadership change represents a pivotal moment for DexCom as it moves forward under new permanent executive leadership.

Investors will be keen to observe Mr. Leach's strategic direction and execution in his permanent CEO role, especially considering the substantial incentive package designed to align his interests with long-term shareholder value. The report also confirms that Kevin R. Sayer is expected to return from his medical leave around March 2026, with Mark Foletta continuing as interim Chairman of the Board until then.

02—Key points

Key Highlights

  1. Jacob S. Leach officially appointed President and CEO, effective January 1, 2026.
  2. Mr. Leach's new annual base salary will be $1,150,000.
  3. He will have an annual target bonus opportunity of 150% of his base salary.
  4. Mr. Leach to receive $7,500,000 in restricted stock units (RSUs) vesting over three years.
  5. Mr. Leach to receive $7,500,000 in performance stock units (PSUs) tied to specific performance conditions.
  6. Kevin R. Sayer is anticipated to return from medical leave around March 2026.
  7. Mark Foletta will continue as interim Chairman of the Board until Mr. Sayer's return.

03—Questions

Frequently Asked Questions

  1. When does Jacob S. Leach officially become CEO?

    Jacob S. Leach's appointment as President and Chief Executive Officer is effective January 1, 2026.

  2. What is the total compensation package for Jacob S. Leach?

    Mr. Leach's compensation package includes an annual base salary of $1,150,000, an annual target bonus of 150% of his base salary, $7,500,000 in restricted stock units vesting over three years, and $7,500,000 in performance stock units tied to specific performance goals. He also remains eligible for the company's severance plan and employee benefit programs.

  3. What is the expected return date for Kevin R. Sayer?

    Kevin R. Sayer is currently expected to return from his medical leave of absence on or about March 2026.

  4. Who is serving as interim Chairman of the Board?

    Mark Foletta will continue to serve as interim Chairman of the Board until Mr. Sayer's return.

04—Continue

← View all 8-K filings